Study designs of evaluations included in the review
Randomised controlled double-blind trials were included.
Specific interventions included in the review
Ramipril (long-acting, nonsulfhydryl angiotensin-converting enzyme inhibitor with pharmacological properties allowing once-daily administration).
Participants included in the review
Patients with chronic congestive heart failure, aged 18 to 80 years, with ejection fraction less than 40% or heart size greater than 600 mL/m2 (men) or 550 mL/m2 (women).
Outcomes assessed in the review
Mortality, hospitalisation, subjective functional status as assessed by NYHA classification, and exercise capacity.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the authors performed the selection.